
Agilent Technologies, Inc. (A)
$
154.37
-2.83 (-1.83%)
Key metrics
Financial statements
Free cash flow per share
4.9193
Market cap
43.8 Billion
Price to sales ratio
6.4473
Debt to equity
0.4976
Current ratio
1.9574
Income quality
1.2254
Average inventory
1 Billion
ROE
0.1931
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Agilent Technologies, Inc. provides application-focused solutions to life sciences, diagnostics, and applied chemical markets globally. The Life Sciences and Applied Markets segment delivers a wide array of analytical instruments and systems, including liquid chromatography systems and components, mass spectrometry systems, gas chromatography systems, and various spectroscopy technologies. The company's innovative approach is evident in its diverse offerings such as cell analysis plate-based assays, flow cytometers, laboratory automation tools, and dissolution testing equipment. Additionally, Agilent incurred an interest expense of $27,000,000.00 reflecting its debt servicing obligations. The gross profit ratio is 0.53 which highlights the efficiency of the company's production and sales operations. Furthermore, the diluted EPS is $1.53 accounting for potential share dilution, while the net income ratio stands at 0.23 demonstrating the company's profitability margin. The reported depreciation and amortization expenses amount to $288,000,000.00 underscoring the wear and tear of its assets. On the diagnostics front, Agilent offers advanced technologies for DNA analysis, including arrays for mutation detection and next-generation sequencing, along with reagents for turbidimetry. In addition, Agilent CrossLab segment delivers essential laboratory supplies and services such as custom chemistries and sample preparation products. The stock is reasonably priced at $126.32 appealing to a broad range of investors. With a high average trading volume of 1,821,525.00 there is strong liquidity in the stock, making it an attractive option for market participants. The company showcases a mid-range market capitalization of $43,763,957,674.00 positioning it as a steady performer within the sector. As a key player in the Medical - Diagnostics & Research industry, Agilent significantly contributes to the overall market landscape, driving innovation and growth within the Healthcare sector. Its comprehensive range of products is marketed through direct sales, distributors, and electronic commerce, ensuring a broad reach in delivering its advanced solutions to a global clientele.
Investing in Agilent Technologies, Inc. (A) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C-, with a Bullish outlook. Always conduct your own research before investing.
Analysts predict Agilent Technologies, Inc. stock to fluctuate between $96.43 (low) and $160.27 (high) in the next 365 days, reflecting market expectations and potential volatility.
As of 2025-11-26, Agilent Technologies, Inc.'s market cap is $43,763,957,674, based on 283,500,406 outstanding shares.
Compared to Eli Lilly & Co., Agilent Technologies, Inc. has a Lower Market-Cap, indicating a difference in performance.
Agilent Technologies, Inc. pays dividends. The current dividend yield is 0.65%, with a payout of $0.26 per share.
To buy Agilent Technologies, Inc. (A) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for A. Place an order (Market, Limit, etc.).
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
Agilent Technologies, Inc.'s last stock split was 699:500 on 2014-11-03.
Revenue: $1,861,000,000 | EPS: $1.53 | Growth: -65.54%.
Visit https://www.agilent.com/investor-relations for detailed financial reports.
You can explore historical data from here
All-time high: $179.57 (2021-09-03) | All-time low: $96.43 (2025-04-09).
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News

seekingalpha.com
Agilent Technologies delivered strong Q4 2025 results, with revenue and EPS beating expectations and robust growth in Life Sciences and Diagnostics segment. Management forecasts FY26 revenue growth of 6% and normalized EPS between $5.86 and $6.00, signaling continued solid performance. Agilent now trades at a 6% premium to fair value after a 23% rally, outpacing the S&P 500 handily since my August coverage.

zacks.com
A report higher Q4 revenues and lifts its 2026 outlook, yet the stock slips as margins narrow across key business segments.

benzinga.com
Agilent Technologies Inc (NYSE: A) reported upbeat earnings for the fourth quarter on Monday.

seekingalpha.com
Agilent Technologies, Inc. ( A ) Q4 2025 Earnings Call November 24, 2025 4:30 PM EST Company Participants Tejas Savant Padraig McDonnell - CEO, President & Director Adam Elinoff - Senior VP, CFO & Principal Financial Officer Rodney Gonsalves - Principal Accounting Officer, VP & Corporate Controller Simon May - SVP & President of LDG Angelica Riemann - Senior VP & President of Agilent CrossLab Group Mike Zhang - Senior VP & President of Applied Markets Group Conference Call Participants Tycho Peterson - Jefferies LLC, Research Division Patrick Donnelly - Citigroup Inc., Research Division Daniel Leonard - UBS Investment Bank, Research Division Douglas Schenkel - Wolfe Research, LLC Brandon Couillard - Wells Fargo Securities, LLC, Research Division Vijay Kumar - Evercore ISI Institutional Equities, Research Division Jack Meehan - Nephron Research LLC Daniel Brennan - TD Cowen, Research Division Michael Ryskin - BofA Securities, Research Division Daniel Arias - Stifel, Nicolaus & Company, Incorporated, Research Division Casey Woodring - JPMorgan Chase & Co, Research Division Catherine Ramsey - Robert W. Baird & Co. Incorporated, Research Division Luke Sergott - Barclays Bank PLC, Research Division Presentation Operator Good afternoon.

seekingalpha.com
Agilent Technologies, Inc. ( A ) Bank of America Global Healthcare Conference 2025 September 25, 2025 4:50 AM EDT Company Participants Padraig McDonnell - CEO, President & Director Conference Call Participants Michael Ryskin - BofA Securities, Research Division Presentation Michael Ryskin BofA Securities, Research Division I'm Mike Ryskin. I'm on the Bank of America Life Science Tools and Diagnostics team based in New York.

zacks.com
While the top- and bottom-line numbers for Agilent (A) give a sense of how the business performed in the quarter ended October 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

zacks.com
Agilent Technologies (A) came out with quarterly earnings of $1.59 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $1.46 per share a year ago.

businesswire.com
SANTA CLARA, Calif.--(BUSINESS WIRE)---- $A #BringGreatScienceToLife--Agilent Technologies, Inc. (NYSE: A) today reported revenue of $1.86 billion for the fourth quarter ended October 31, 2025, exceeding revenue guidance and representing growth of 9.4% reported and up 7.2% core(1) compared with the fourth quarter of 2024. Fourth-quarter GAAP net income was $434 million, or $1.53 per share. This compares with $351 million, or $1.22 per share, in the fourth quarter of 2024. Non-GAAP(2) net income was $452 million, or $1.59 per.

reuters.com
Life sciences firm Agilent Technologies on Monday beat fourth-quarter revenue estimates, helped by strong demand for medical tools and equipment used in lab research and diagnostic services.

benzinga.com
Agilent Technologies, Inc. (NYSE: A) will release earnings results for the fourth quarter, after the closing bell on Monday, Nov. 24.
See all news